ASTH three-lens brief
Evidence-based stock research on ASTH. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Analyst mean target $51.50 — 35% above current (8 analysts). · Trading >3% below the 50-day MA — short-term weakness.
- Trading >3% below the 50-day MA — short-term weakness.
- Analyst mean target $51.50 — 35% above current (8 analysts).
ASTH closed at $38.03 (-0.08%) as of 2026-09-11. Market cap: $1.89B. P/E (trailing) 46.4. Price is below the 50-day MA and above the 200-day MA. Positives: analyst mean target $51.50 — 35% above current (8 analysts).. Concerns: trading >3% below the 50-day MA — short-term weakness.. Last quarter: Revenue $972.52M, net income $19.74M, free cash flow $231.19M.
Why three lenses on ASTH, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ASTHacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ASTH" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ASTH brief"></iframe>